Illumina

Illumina reported Q3 revenue of $1.13 billion (below consensus) with a gross margin of 69.4% and adjusted earnings per share of $1.44, both above expectations. The company raised its full-year guidance for revenue and adjusted EPS. Investors still punished the stock sharply because the valuation remains high (P/E around 44) and recent re-ratings prompted profit-taking. » Mere på deraktionaer.de

Illumina generates recurring, highly profitable revenue from selling gene sequencing instruments and the consumables that are essential to use them. With about 80% market share, the company benefits from economies of scale and high switching costs for customers. The growing use of genome sequencing in clinical care and early detection, especially in cancer therapies, provides sustained demand tailwinds. » Mere på finanzen.net

Illumina has recovered after years of weakness: following the failed GRAIL deal and legal costs, the company is returning to organic growth. Second-quarter revenue rose 6.5% to $1.16 billion, with a markedly stronger North America business. The stock is up about 125% year-to-date and hit a multi‑year high, fueled by prospects of rising demand for sequencing and companion diagnostic solutions for personalized cancer vaccines such as those from Moderna and Merck. Investors have already benefited from strong price gains as Illumina expands its market position in sequencing technology and bioinformatics. » Mere på deraktionaer.de

Illumina will be added to the S&P 500 on September 21, 2026, which is expected to create short-term passive buying pressure. Sustained demand in clinical sequencing is driving core growth, supported by sequencing instruments such as NovaSeq and recurring revenue from consumables. The strengthened profile is shifting management's focus toward margin expansion in the core business. » Mere på finanzen.net

Illumina significantly beat analysts’ expectations for revenue and earnings in Q2 and materially increased its outlook for 2026. Record growth in diagnostic consumables and demand for the NovaSeq X platform are driving recurring revenue. Institutional investors responded with massive buying pressure at high volume. » Mere på finanzen.net